Abstract Autologous bone marrow mononuclear cell (BM-MNC) therapy for patients with ST-segment elevation myocardial infarction (STEMI) has produced inconsistent results, possibly due to BM-MNC product heterogeneity. Patient-specific cardiovascular risk factors (CRFs) may contribute to variations in BM-MNC composition. We sought to identify associations between BM-MNC subset frequencies and specific CRFs in STEMI patients. Bone marrow was collected from 191 STEMI patients enrolled in the CCTRN TIME and LateTIME trials. Relationships between BM-MNC subsets and CRFs were determined with multivariate analyses. An assessment of CRFs showed that hyperlipidemia and hypertension were associated with a higher frequency of CD11b
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Introduction
End-stage heart failure results in the deaths of more than 60,000 patients annually in the US. In the western world, the leading cause of heart failure is ischemic heart disease [59] . Several approaches have been proposed for the A. Contreras and A. Orozco contributed equally to this work.
& Lem Moyé lemmoye@msn.com treatment of patients with ischemic heart disease (IHD), one of which is stem cell therapy. Although stem cell therapies have shown promise in preclinical studies as a treatment for IHD [22, 25, 33, 40] , clinical trials have produced inconsistent results [1, 10, 13, 16, 20, 51, 52, 58] . Thus, efforts are underway to determine ways to optimize these therapies.
Patients with IHD have a wide range of cardiovascular risk factors (CRFs). In a study by Nauta et al. [32] , 69.3% of patients with acute myocardial infarction (MI) had at least one CRF; from those, 39.2% had a single CRF, 21.7% had 2, and 8.4% had 3 or 4. These CRFs have been shown to correlate with changes in the frequencies of particular cell types in the blood. Recently, it was reported that hypertension is associated with an increase in the level of circulating CD11b
? cells [38] , advanced age and smoking are associated with a decrease in circulating CD31
? leukocytes [14] , age is inversely associated with the level of CD34
? cells [30] , and diabetes is associated with a decrease in circulating endothelial progenitor cells [26] .
Changes in the cellular composition of the blood and bone marrow (BM) could affect the outcomes of IHD. For example, Cogle et al. [8] showed a negative correlation between the percentage of CD11b
? cells in the BM and post-infarct left ventricular ejection fraction (LVEF) in patients with ST-segment elevation myocardial infarction (STEMI), regardless of whether they received BM mononuclear cells (BM-MNCs) or placebo. In addition, Schutt et al. [41] found that infarct size reduction after STEMI was greater in patients who had a higher percentage of CD31
? mononuclear cells in the BM. We hypothesized that a patient's CRFs may affect the frequencies of specific angiogenic, lymphocytic, monocytic, and hematopoietic cells within the BM, which could, in turn, impact the efficacy of autologous BM-MNC therapies. To test this hypothesis, we assessed the relationships between the frequencies of BM-MNCs expressing CD34, CD31, CD3, CD14, CD11b, CD19, CD45, and C-X-C chemokine motif receptor 4 (CXCR4) and 8 CRFs in patients with STEMI.
Methods
For this retrospective analysis, our study cohort comprised patients who participated in the Cardiovascular cell therapy research network (CCTRN) transplantation in myocardial infarction evaluation (TIME) and LateTIME trials and provided consent to have their remaining BM-MNC product further analyzed at the CCTRN Biorepository [51] [52] [53] [54] 62] . The CCTRN TIME and LateTIME trials had similar inclusion criteria but differed in the timing of BM aspiration and cell delivery after STEMI. Institutional Review Boards at each clinical site approved the protocols for both trials, and all participants provided written informed consent.
Flow cytometry
BM-MNC samples collected at baseline (i.e., before treatment) were immunophenotyped via polychromatic flow cytometry to determine the frequency of hematopoietic, lymphocytic, monocytic, and angiogenic precursors in the BM, as previously described [51, 53] . Briefly, 1-5 million BM-MNCs incubated with antibodies against CD34, CD11b, CD31, CD45, CD3, CD14, CD19, and CXCR4 for 20 min at 4°C in the dark, washed twice in 2.5% phosphate-buffered saline (PBS), and then resuspended to a final volume of 1 mL in 2.5% PBS for flow cytometry analysis. Samples were analyzed with an LSR II flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA), and the data were analyzed with the FlowJo software (Tree Star, Inc., Ashland, OR, USA). All analyses were performed on gated lymphocytes or monocytes or using the International Society of Hematotherapy and Graft Engineering (ISHAGE) gating strategy [45] . Figures 1 and 2 show examples of the gating strategies used to determine the frequencies of specific lymphocyte, monocyte, and hematopoietic stem cell populations in the BM samples.
Statistical analyses
Patients from the TIME and LateTIME studies were combined into a single cohort for all analyses. Demographic data are shown as counts and percentages for dichotomous and polychotomous variables and as means and standard deviations for continuous variables. We calculated the associations between the frequencies of eight BM-MNC subsets (Table 1) ; specifically, each of the subsets was the dependent variable in a multiple regression model that contained one of eight CRFs (self-reported hypertension, hyperlipidemia, diabetes mellitus, and smoking, as well as sex, age, creatinine level, and blood glucose level) plus a dichotomous variable reflecting the study (TIME or LateTIME). In this exploratory analysis, no corrections made for multiplicity. All analyses conducted using SAS 9.3 (SAS Institute, Cary, NC, USA).
Results

Baseline clinical characteristics
The current study included 191 patients who provided consent for BM analysis by the CCTRN Biorepository.
Demographic and CRF data for the current study cohort are reported in Table 2 . The mean age of the population analyzed was 56 years (standard deviation, 11), and only 15% (n = 28) of the participants were female.
Associations between cardiovascular risk factors and BM-MNC subsets
A multivariable model was used to explore the relationships between eight CRFs (hyperlipidemia, hypertension, ? CD3 ? T-cell precursors. These data suggest that in our cohort of patients with STEMI, CRFs thought to influence IHD outcomes may have also affected the cellular composition of the BM, particularly the frequency of specific monocyte and lymphocyte subsets.
Discussion
Exploratory studies conducted in conjunction with the CCTRN TIME, LateTIME, and FOCUS trials have shown associations between specific BM-MNC subsets and clinical outcomes [35, 49, 51, 52] . It has been suggested that CRFs, such as age and sex, play an important role in a patient's response to cell therapy [47, 61] . However, to date, there has been no comprehensive assessment of how patient characteristics may alter BM composition in STEMI patients; thus, it is unknown whether or how the Lymphocytes (B cell) Improvement in heart function [34, 48, 49] AMI acute myocardial infarction, LVEF left ventricular ejection fraction composition of autologous BM-MNC products may be altered by patients' CRFs.
In the current study, we looked for associations between specific BM-MNC subsets and eight CRFs in STEMI patients enrolled in either the TIME or LateTIME trials. Hypertension, hyperlipidemia, sex, smoking, age, glucose, and creatinine levels were found to be associated with differences in BM composition in these patients. These data suggest that each patient's BM composition differs according to the individual's CRF profile. Thus, these attributes may affect the composition of the autologous BM-MNC therapy received and the associated outcomes.
An inflammatory process that involves the transmigration and accumulation of both innate and adaptive immune cells into the interstitium of affected tissues may play a role in hypertension [28] . Furthermore, hypertension has been associated with atherosclerosis, endothelial dysfunction, and the accumulation of monocytes within the endothelium [17] . However, the effects of hypertension on human BM monocytes are not defined. In this study, hypertension was positively associated with the frequency of CD11b
? cells in the BM. To our knowledge, our study is the first to describe an association between hypertension and the level of BM monocytes in humans. Increased expression of CD11b is suggested to stimulate the development of IHD by promoting myocyte oxidative injury and myocardial hypertrophy [12, 31] . Interestingly, Cogle et al. [8] found that an increased level of CD11b
? cells in the BM of patients at 1-3 weeks after acute MI was associated with worse LVEF at the 6-month follow-up. Our results suggest that hypertension may predispose an individual to increased levels of CD11b
? cells and, thereby, to poor outcomes after STEMI.
Hyperlipidemia, a well-known CRF, is associated with plaque formation and vessel rupture [3] by increased endothelial permeability to LDL cholesterol. In our study, we found an association between the frequency of CD11b ? cells and hyperlipidemia. Similarly, Serrano et al. [42] observed an increase in the circulating numbers of CD11b ? cells in patients with untreated hypercholesterolemia. Furthermore, they observed decreased numbers of circulating CD11b
? cells and LDL cholesterol in these patients after treatment. These findings suggest that this cell type plays an important role in the pathogenesis of atherosclerosis.
Increased age is a major contributor to endothelial dysfunction [5, 6, 11, 43, 44, 46] and an increased risk of developing IHD [39] . In our study, increased age was inversely associated with the frequency of CD45
? CD31
?
lymphocytes. This is similar to the findings of, both Hur et al. [19] and Ge et al. [14] who showed an inverse correlation between the level of circulating peripheral blood CD31 ? T cells and age. One possible explanation for this decrease in cell number with age is age-related apoptosis. Kushner et al. [27] showed that caspase-3, a critical downstream protein involved in the execution phase of the apoptotic pathway, is higher in CD31
? T cells of middleaged and older men than in those of younger men, supporting this correlation between age and apoptosis of CD31
? cells. Interestingly, increased age has been shown to be associated with increases in cellular apoptosis more broadly and of course with the incidence of cardiovascular disease [28] . This loss of angiogenic lymphocytes with age, or immunosenescence of multiple cell types, suggests that the BM-MNC products from elderly patients may be less effective as a cell therapy. Another cell type shown to change in frequency with age is CD34
? cells. Moresi et al. [30] found that the number of circulating CD34
? cells significantly decreased with increasing age in a population of healthy individuals (age range 16-100 years old). Although our results showed a similar trend, the association was not statistically significant. The lack of significance may have been due to differences in the sample types assessed (blood vs bone marrow) or due to differences in the age range and health status of the respective study participants. Because the patients in our study had sustained an MI recently, the CD34
? stem cells may have been released into circulation in response to the recent injury, thereby masking the effects of age on this cell population.
Furthermore, female sex has been found to be associated with a lower risk of death due to coronary artery disease after adjustment for CRFs and age [55] . In this study, female sex was associated with decreased levels of BM CD11b ? and CD45 ? CD14 ? monocytes. Sex steroids, including estrone, progesterone, and testosterone, can modulate the ability of monocytes and platelets to adhere to endothelial cells and, therefore, can either induce or inhibit the initiation and progression of vascular lesions [9] . Estrone, which is higher in women than in men, reduces the surface expression of CD11b and decreases monocyte adhesion to endothelial cells exposed to the pro-inflammatory agent lipopolysaccharide, suggesting that it may inhibit endothelial injury under inflammatory conditions [9] . Although we did not measure the serum levels in our cohort of patients, it is known that estrone production does not stop after menopause [15] . Similar to our results, Heimbeck et al. [18] found that the level of circulating CD45
? CD14 ? monocytes is lower in women than in men. The reported effect size is the model coefficient from a multiple linear regression model with the cell type as the independent variable and the cardiovascular risk factor as the dependent variable. The reported P values are adjusted for study (TIME or LateTIME). All cells were analyzed within the lymphocyte gate unless otherwise specified CI confidence interval a Analyzed using ISHAGE gating b Analyzed within the monocyte gate Finally, cigarette smoking may cause apoptotic cell death and cellular senescence, and may inhibit repair functions [24] . We found that smoking was associated with a decrease in BM CD45
? CD31 ? lymphocytes. Similar to our findings, Ge et al. [14] found a negative association between smoking and the level of circulating CD45
?-
CD31
dim lymphocytes in healthy men and women. Further investigation of this cell type is warranted to determine its role in the prevention or repair of cardiac injury.
Study limitations
This study had several limitations. Before the TIME and LateTIME trials began, we chose the BM-MNC phenotypes and CRFs to assess based on the current knowledge of the factors that affect the repair process after acute MI, balanced by available fiscal resources. The fields of cardiovascular regeneration and cell therapy have evolved rapidly since the design of TIME and LateTIME studies; recent studies have revealed multiple cell types that may contribute to cardiovascular outcomes. Unfortunately, some of the cell populations that are now recognized as important in this field were either not understood 8 years ago or were too costly to evaluate in the first in-depth analysis, and thus were not included in the design of TIME and LateTIME. In particular, cell populations involved in pro-inflammatory responses, such as CD14
? [56] . We identify this as a shortcoming of the study design. Unfortunately, because cell phenotypes can only be analyzed in fresh samples, we are not able to assess these newly recognized phenotypes. Despite this, we feel that our results provide a relatively comprehensive assessment of BM phenotypes in patients with STEMI. Another limitation was that the BM-MNC products were obtained from a cohort of patients with multiple risk factors, potentially making it difficult to discern associations between specific BM-MNC frequencies and individual CRFs. In addition, all the patients in this study had an STEMI event before the BM-MNCs were collected, which could have overshadowed other factors affecting the composition of the BM. Moreover, the timing between the STEMI event and BM-MNC collection varied among patients. Finally, because our study had a low number of patients in some demographic (e.g., females) and CRF groups (e.g., diabetes), the statistical power for these groups may have been too low to detect all associations between these factors and BM-MNC populations.
Conclusions
To our knowledge, this is the first study to show associations between specific CRFs and the frequencies of particular BM-MNC subsets, including monocytes and lymphocytes, in patients with STEMI. Because of the exploratory nature of this study, we cannot determine whether the CRFs directly affected the BM composition or if other factors contributed to this association. Future studies will be necessary to assess whether a cause-andeffect relationship exists. Since the BM obtained from patients who had hyperlipidemia or hypertension who were advanced in age or who smoked showed changes that would be expected to be unfavorable for cardiac repair, our results suggest that the BM product from these patients may be less effective as a cell therapy than that from healthier individuals. If this is proven to be true, patients' CRFs may need to be considered when designing future autologous cell therapy studies and assessing clinical outcomes.
